Skip to content
Peptigraph home

Sermorelin and CJC-1295 + Ipamorelin Together: What Is Known

Sermorelin and CJC-1295 + Ipamorelin taken together: what each one is, how each is regulated, and what is known about combining them.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
GHRH analogCompounded by prescriptionSermorelinGHRH analog once FDA-approved as Geref and since discontinued; in an uncontrolled pediatric study mean height velocity rose from 4.1 to 8.0 cm/yr after 6 months.[15]Growth hormoneGHRH + GHRP blendNot FDA approved · research blendCJC-1295 + IpamorelinUnapproved blend of CJC-1295 (no DAC) and ipamorelin; an FDA Drugs@FDA search for the CJC-1295 component returned no matches, so no approved product was found.[16]Growth hormone
Interaction notes

Timing, interactions and safety

Evidence for the combination

No studies tested these together (PubMed search: 4 results, 2 Oct 2026).

Neither is FDA approved for use in people, and we have no sourced data on combining them.
Each component

Side by side

Showing 8 of 12 fields where the two differ. Category, PCAC vote, Jul 2026, WADA, Evidence strength are the same or both unknown.

FieldSermorelinCJC-1295 + Ipamorelin
ClassGHRH analogGHRH + GHRP blend
Also called—CJC/Ipa
FDA statusCompounded by prescriptionNot FDA approved · research blend
Anti-doping detection
  • A urine assay detects CJC-1295 and other GHRH analogues at very low concentrations.PMID 35298973
  • Labs expect GHRH analogues like CJC-1295 to be hard to find because of tiny urine concentrations; the study reports no detections in routine anti-doping samples.PMID 34665524
  • After nasal dosing, ipamorelin metabolites were still found in urine after the parent drug was gone (samples were collected for 2 days).PMID 25869809
Half-lifeNo published half-life foundPubMed search, 11 Oct 2026Ipamorelin: 2 hours terminal half-lifeintravenous infusion (15 min) · Pharmaceutical research 1999, PMID 10496658
Human studies we summarised6 human (1 randomized or controlled) of 9 summarised6 human (3 randomized or controlled) of 19 summarised, across ingredients
Typical study doses
Vial sizes sold2 mg, 5 mg, 9 mg, 15 mg10 mg
Related tools

Sermorelin vs CJC-1295 + Ipamorelin

Choosing between the two rather than combining them? The comparison lines them up field by field.

Open the comparison

The closest human data pairs sermorelin with other peptides

The closest human study is a chart review of men on testosterone given GHRP/sermorelin combination therapy: mean continuous treatment lasted 134 days and mean posttreatment IGF-1 was 239.0 ng/mL.[5]

Its authors suggest the combination may be beneficial in men with wasting conditions that can improve with increased GH secretion. That is their suggestion, not a measured outcome.[5]

In healthy older men, sermorelin-type GHRH given nightly raised nocturnal GH release.[6]

What is known about the blend

CJC-1295's human studies are in healthy adults and measure GH and IGF-I.[13]

Ipamorelin's randomised trial found no significant difference from placebo in its key and secondary efficacy analyses.[12]

A PubMed search on 2 Oct 2026 for CJC-1295 plus ipamorelin together with sermorelin matched 4 records; none is recorded as a trial of the combination.

Calculated from pubmed query (("CJC-1295"[tiab] OR CJC1295[tiab]) AND (ipamorelin[tiab])) AND (sermorelin[tiab] OR Geref[tiab]); records matched 4; search date 2026-10-02. Formula: records_matched = PubMed count recorded in combinations.json for the query on search_date

Regulatory and sport status

Sermorelin's sole FDA entries are discontinued Geref records.[18]

FDA reports serious adverse events for CJC-1295, including increased heart rate and vasodilatory reaction.[19]

WADA's list names sermorelin and CJC-1295 together as GHRH analogues.[1]

Common questions

Sermorelin vs CJC-1295 ipamorelin: which is better?

No trial compares them. Sermorelin has paediatric trials and a discontinued brand; the blend has human data only for its separate components.[15]

Can sermorelin be stacked with CJC-1295 and ipamorelin?

No study has tested that combination. The nearest report combined sermorelin with GHRP-6 and GHRP-2 in men on testosterone.[5]

Sources

  1. 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  2. 2An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
  3. 3Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
  4. 4Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.The Journal of clinical endocrinology and metabolism · 1992PMID 1379256Accessed 2 Oct 2026
  5. 5Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels.American journal of men's health · 2017PMID 28830317Accessed 2 Oct 2026
  6. 6Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.Metabolism: clinical and experimental · 1997PMID 9005976Accessed 2 Oct 2026
  7. 7PubMed search: (sermorelin[tiab] OR Geref[tiab]) (34 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  8. 8PubMed search: (sermorelin[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab] OR "GHRH 1-29"[tiab]) AND (elderly[tiab] OR aging[tiab] OR "older adults"[tiab] OR adults[tiab]) AND (treatment[tiab] OR therapy[tiab] OR administration[tiab]) (15 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  9. 9PubMed search: (sermorelin[tiab] OR Geref[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  10. 10Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin.Drug testing and analysis · 2015PMID 25869809Accessed 2 Oct 2026
  11. 11Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.Pharmaceutical research · 1999PMID 10496658Accessed 2 Oct 2026
  12. 12Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.International journal of colorectal disease · 2014PMID 25331030Accessed 2 Oct 2026
  13. 13Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.The Journal of clinical endocrinology and metabolism · 2006PMID 16352683Accessed 2 Oct 2026
  14. 14PubMed search: (("CJC-1295"[tiab] OR CJC1295[tiab]) AND (ipamorelin[tiab])) AND (sermorelin[tiab] OR Geref[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  15. 15Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.The Journal of clinical endocrinology and metabolism · 1996PMID 8772599Accessed 2 Oct 2026
  16. 16Drugs@FDA (openFDA) search: active ingredient "CJC-1295"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  17. 17PubMed search: (sermorelin[tiab] OR Geref[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (21 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  18. 18Drugs@FDA (openFDA) search: active ingredient "sermorelin"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  19. 19Official web pageOfficial web page · web page

Found an error? Report a correction.